Eliadis P, Mais A, Papazisis A, Loxa E, Dimitriadis A, Sarrigeorgiou I
Vaccines (Basel). 2024; 12(8).
PMID: 39204038
PMC: 11359269.
DOI: 10.3390/vaccines12080914.
Parikh U, Heaps A, Moisi D, Gordon K, Mellors J, Choudhary M
Pathog Immun. 2024; 9(2):58-78.
PMID: 39165724
PMC: 11335343.
DOI: 10.20411/pai.v9i2.715.
Rivera-Perez D, Mendez C, Diethelm-Varela B, Melo-Gonzalez F, Vazquez Y, Meng X
Front Immunol. 2024; 15:1372193.
PMID: 38812507
PMC: 11133585.
DOI: 10.3389/fimmu.2024.1372193.
Bladh O, Aguilera K, Marking U, Kihlgren M, Greilert Norin N, Smed-Sorensen A
Front Immunol. 2024; 15:1346749.
PMID: 38558811
PMC: 10978617.
DOI: 10.3389/fimmu.2024.1346749.
Matsumoto N, Sasaki A, Kadowaki T, Mitsuhashi T, Takao S, Yorifuji T
Sci Rep. 2024; 14(1):4564.
PMID: 38403650
PMC: 10894855.
DOI: 10.1038/s41598-024-55245-9.
A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates.
Tedjakusuma S, Lester C, Neuhaus E, Dora E, Gutierrez S, Braun M
Vaccines (Basel). 2024; 12(2).
PMID: 38400116
PMC: 10893453.
DOI: 10.3390/vaccines12020132.
Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in....
Erice A, Prieto L, Caballero C
Vaccines (Basel). 2023; 11(12).
PMID: 38140239
PMC: 10748336.
DOI: 10.3390/vaccines11121835.
Co-evolution of SARS-CoV-2 variants and host immune response trajectories underlie COVID-19 pandemic to epidemic transition.
Maurya R, Swaminathan A, Shamim U, Arora S, Mishra P, Raina A
iScience. 2023; 26(12):108336.
PMID: 38025778
PMC: 10663816.
DOI: 10.1016/j.isci.2023.108336.
Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
Li J, Li J, Dai S, Dang L, Wang L, Cao L
Front Immunol. 2023; 14:1269665.
PMID: 37828994
PMC: 10565032.
DOI: 10.3389/fimmu.2023.1269665.
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections.
Selva K, Ramanathan P, Haycroft E, Reynaldi A, Cromer D, Tan C
JCI Insight. 2023; 8(18).
PMID: 37737263
PMC: 10561726.
DOI: 10.1172/jci.insight.172470.
Mucosal antibody responses following Vaxzevria vaccination.
Selva K, Ramanathan P, Haycroft E, Tan C, Wang L, Downie L
Immunol Cell Biol. 2023; 101(10):975-983.
PMID: 37670482
PMC: 10952200.
DOI: 10.1111/imcb.12685.
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
Ingelman-Sundberg H, Blixt L, Wullimann D, Wu J, Gao Y, Healy K
Haematologica. 2023; 109(2):646-651.
PMID: 37646668
PMC: 10828773.
DOI: 10.3324/haematol.2023.282894.
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
Hornsby H, Nicols A, Longet S, Liu C, Tomic A, Angyal A
Nat Commun. 2023; 14(1):5065.
PMID: 37604803
PMC: 10442364.
DOI: 10.1038/s41467-023-40592-4.
Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G, Murugesan D, Raghavan S, Chattopadhyay S, Mehdi F, Ayushi
Indian J Med Res. 2023; 157(6):509-518.
PMID: 37322634
PMC: 10466496.
DOI: 10.4103/ijmr.ijmr_2521_22.
Future COVID-19 Booster Vaccine Refusal in Healthcare Workers after a Massive Breakthrough Infection Wave, a Nationwide Survey-Based Study.
Gu F, Lin H, Chen Z, Ambler G, Chen X, Chen X
Vaccines (Basel). 2023; 11(5).
PMID: 37243091
PMC: 10222960.
DOI: 10.3390/vaccines11050987.
High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.
Groenheit R, Bacchus P, Galanis I, Sonden K, Bujila I, Efimova T
Emerg Infect Dis. 2023; 29(6):1240-1243.
PMID: 37141616
PMC: 10202879.
DOI: 10.3201/eid2906.221862.
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.
Nouailles G, Adler J, Pennitz P, Peidli S, Teixeira Alves L, Baumgardt M
Nat Microbiol. 2023; 8(5):860-874.
PMID: 37012419
PMC: 10159847.
DOI: 10.1038/s41564-023-01352-8.
Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020-2022 in a Japanese medical center.
Kanamori R, Yan Y, Ito K, Fukuda H, Hori S, Yamamoto T
Sci Rep. 2023; 13(1):4941.
PMID: 36973531
PMC: 10040914.
DOI: 10.1038/s41598-023-32193-4.
Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.
Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M
JAMA Netw Open. 2023; 6(2):e2255978.
PMID: 36790811
PMC: 9932849.
DOI: 10.1001/jamanetworkopen.2022.55978.
Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.
Sun K, Tempia S, Kleynhans J, von Gottberg A, McMorrow M, Wolter N
Nat Commun. 2023; 14(1):246.
PMID: 36646700
PMC: 9842214.
DOI: 10.1038/s41467-022-35652-0.
